Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pro Medicus Limited ( (AU:PME) ) has provided an announcement.
Pro Medicus Limited has secured a significant A$170 million, 10-year contract with UCHealth, a Colorado-based healthcare system, to implement its Visage 7 Enterprise Imaging Platform across UCHealth’s network. This strategic move enhances Pro Medicus’s position in the North American market by replacing UCHealth’s legacy systems with a unified, cloud-based solution, potentially setting a new standard in healthcare imaging technology.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a leading health imaging company that provides advanced imaging solutions through its wholly-owned U.S. subsidiary, Visage Imaging, Inc. The company specializes in cloud-based enterprise imaging platforms, offering products like Visage 7 Viewer, Visage 7 Workflow, and Visage 7 Open Archive, with a focus on the North American healthcare IT market.
Average Trading Volume: 236,346
Technical Sentiment Signal: Buy
Current Market Cap: A$29.43B
For an in-depth examination of PME stock, go to TipRanks’ Overview page.